Peptide evidence guide
Sermorelin is a peptide used to stimulate growth-hormone release. Understanding that mechanism is the starting point—not proof of an anti-aging benefit.
By the Get Peptide Reviews editorial team · Researched September 25, 2026 · Our review method
What to know first: historical Geref products and the compounded sermorelin programs marketed today are different regulatory questions. Early human research supports an effect on hormone measurements; it does not by itself establish longer life, better recovery or broad wellness benefits from a modern clinic’s formulation.
Affiliate disclosure: we may earn a commission if you enroll through a provider button. These are commercial comparisons, not clinical recommendations. How our links work.
What is sermorelin, and how does it work?
Sermorelin is a synthetic fragment of growth hormone–releasing hormone, often described as GHRH(1–29). It acts upstream of growth hormone: the intended action is to stimulate the pituitary’s release rather than supply growth hormone directly. A change in this pathway can alter growth hormone and insulin-like growth factor 1 (IGF-1) measurements [1].
That distinction does not automatically make a treatment safer or better. A biological mechanism explains why researchers study a substance. Whether a particular person benefits depends on the condition being treated, the formulation, the outcome measured and the quality of the relevant evidence.
What does the human evidence actually show?
A 1992 study by Corpas and colleagues studied ten older men using GHRH(1–29) during short treatment periods, with nine younger men providing baseline comparison data. The researchers observed increases in growth hormone and IGF-1 measures at the higher studied exposure [1]. The small sample and short duration limit what can be concluded.
| Question | What this study supports | What it does not establish |
|---|---|---|
| Does the pathway respond? | Hormone measurements changed in the studied older men. | That every person, formulation or schedule will respond similarly. |
| Does it improve everyday health? | It provides a reason for further research. | Long-term improvements in lifespan, strength, fatigue or day-to-day function. |
| Does it validate a clinic’s product? | No product-specific conclusion about today’s telehealth offers. | Equivalent absorption, quality or results for tablets, injections or blends. |
This is a focused explanation of a primary human study, not a systematic review of every GHRH publication. Research on another analog, including tesamorelin, should be identified by name rather than counted as if it tested the exact sermorelin product being offered.
Use our clinical evidence checklist: match the molecule, route, population, comparator, duration and outcome to the claim. Before-and-after photographs and customer testimonials cannot answer those questions on their own.
Is sermorelin FDA-approved?
Geref is part of sermorelin’s historical FDA record. A 2013 FDA determination states that the discontinued Geref injection products were not withdrawn for safety or effectiveness reasons [2]. That finding concerns those historical products; it is not approval of current compounded formulations or adult anti-aging advertising.
FDA explains that compounded drugs are not FDA-approved and are not evaluated by the agency for safety, effectiveness and quality before they are marketed [3]. Ask the prescriber and pharmacy to identify exactly what they propose to dispense. Read our separate Geref regulatory-history article for the dated withdrawal record.
“A clinician prescribed it,” “made by a pharmacy,” and “FDA-approved drug” describe different facts. Keep them separate when reading peptide reviews.
Risks and safety questions to take to a clinician
The small, short hormone study above cannot settle long-term safety. A prescriber should review your medical history, current medicines, treatment goal and whether evaluation for another cause of symptoms is needed. Ask what testing or follow-up would be appropriate and what findings would make them stop or change the plan.
Compounding adds product-quality questions. FDA warns that poor preparation can produce contamination or an incorrect amount of active ingredient [3]. For any injection, ask about the dispensing pharmacy, handling instructions and whom to contact if the product arrives in an unsuitable condition. Do not infer a product-specific side-effect rate from a study of a different drug or blend.
This guide does not provide an injection schedule, dose or stacking protocol. Follow the prescribing clinician’s and dispensing pharmacist’s instructions for an individually prescribed product.
Sermorelin vs tesamorelin: why the distinction matters
Both names appear in growth-hormone discussions, but their clinical and regulatory records are not interchangeable. Egrifta WR’s tesamorelin label concerns excess abdominal fat in adults with HIV-associated lipodystrophy and says it is not indicated for weight-loss management [4]. That indication should not be generalized to sermorelin or to routine weight-loss treatment.
Read our tesamorelin vs sermorelin comparison for the study populations, approval distinctions and practical questions.
What does online sermorelin cost?
In our September 25 provider check, Embody advertised $99/month. He & She MD listed $229 for one month and monthly equivalents of $179, $159 and $149 for three-, six- and twelve-month plans. These are advertised commercial terms, not evidence that products or services are equivalent [5–6].
Our online sermorelin provider comparison adds Luvo’s four-week billing and explains how to compare the supply periods. For a two-brand decision, read Embody vs He & She MD.
Published monthly offer
Embody sermorelin
$99 / month advertised
Compare the selected formulation, supplied quantity and renewal arrangement.
See Embody sermorelin plansChoice of plan lengths
He & She MD
$229 / one-month plan
Published monthly equivalents fall to $149 with a twelve-month supply purchase.
See He & She MD sermorelinAffiliate disclosure: we may earn a commission if you enroll through a provider button. These are commercial comparisons, not clinical recommendations. How our links work.
Questions before booking a consultation
- What condition or goal are we evaluating, and what evidence applies to me?
- What exact drug, formulation and pharmacy would be used?
- What baseline assessment and follow-up are appropriate?
- Which effects or symptoms should prompt a call, and how do I reach the clinician?
- What does the complete quote include, and what happens if treatment is declined?
Open the complete consultation checklist or return to our peptide reviews and research hub.
Sources and research notes
Primary sources checked September 25, 2026. Addresses below are provided as plain text so you can identify and check each document.
-
Corpas E et al. — GHRH(1–29) study in older men. Journal of Clinical Endocrinology & Metabolism, 1992;75:530–535. PMID 1379256
https://pubmed.ncbi.nlm.nih.gov/1379256/ -
FDA — Determination concerning discontinued Geref injection products, March 2013
https://public-inspection.federalregister.gov/2013-04827.pdf -
FDA — Understanding the Risks of Compounded Drugs
https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs -
FDA — Egrifta WR prescribing information, March 2025
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf -
Embody — Sermorelin Therapy, public offer
https://sermorelin.joinem.co/ -
He & She MD — Sermorelin Injectable, public plan table
https://heandshemd.com/longevity/sermorelin/
This is consumer research, not medical advice or a personal treatment recommendation. We did not buy treatment, complete medical intake or test clinical outcomes. No medical-review credential is claimed. Send a documented correction.